Succinic Acid

Succinic Acid

SCHEMBL507995

Clc1ccc2c(c1NCc1ccc(OC3CCCCCC3)cc1)CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 1/20 0.35
HTR2C known ✓ P28335 2/20 0.34
HTR2A known ✓ P28223 1/20 0.34
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
FFAR4 Q5NUL3 5/20 0.38
FAAH O00519 1/20 0.36
NAAA Q02083 1/20 0.36
UTS2R Q9UKP6 1/20 0.35
P2RX3 P56373 1/20 0.35
ALOX12 P18054 1/20 0.35
S1PR1 P21453 1/20 0.35
HTR2B P41595 1/20 0.34
P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10230108 0.92 ALDH1A1 (0.41) ALDH1A1TSHRNAAAUTS2RHRH1
SCHEMBL506845 0.92 ALDH1A1 (0.41) ALDH1A1TSHRNAAAUTS2RHRH1
SCHEMBL507236 0.92 ALDH1A1 (0.42) ALDH1A1TSHRUTS2RHRH1ALOX12
Succinic Acid SCHEMBL508235 0.88 FFAR4 (0.33) ALDH1A1TSHRFFAR4UTS2RP2RX3
Succinic Acid SCHEMBL2588679 0.88 HDAC1 (0.40) ALDH1A1HTR2CHTR2AHTR2B
Succinic Acid SCHEMBL2590730 0.87 FFAR4 (0.32) FFAR4FAAHS1PR1HTR2CHTR2A
Succinic Acid SCHEMBL2584797 0.87 FFAR4 (0.32) FFAR4FAAHS1PR1HTR2CHTR2A
Succinic Acid SCHEMBL507855 0.86 ITGB3 (0.43) ALDH1A1
Succinic Acid SCHEMBL507443 0.86 HTR2B (0.36) ALDH1A1HTR2CHTR2AHTR2BP2RX7
Succinic Acid SCHEMBL507541 0.84 SRD5A2 (0.35) ALDH1A1HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 HRH1 206/4885HTR2C 1/4885HTR2A 4/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A HRH1 276/4885HTR2C 1/4885HTR2A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.